Ayala Pharmaceuticals, Inc. – NASDAQ:AYLA

Add to watchlist

Market closed

Open in about 15 hours

+25.65%

month

-28.27%

quarter

-90.98%

year

Market Cap	N/A
Enterprise value	N/A

P/E	-0.27
EV/Sales	-4.31
EV/EBITDA	0.08
Price/Sales	14.08
Price/Book	1.01
PEG ratio	N/A
EPS	-2.48

Revenue	692K
EBITDA	-37.42M
Income	-38.01M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	-5182.28%
Oper. margin	-5059.97%
Gross margin	-179.9%
EBIT margin	-5059.97%
EBITDA margin	-5408.82%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA): Profit margin
Mar 2022	458K	-10.02M	-2189.3%
Jun 2022	38K	-8.21M	-21605.26%
Sep 2022	91K	-10.18M	-11195.6%
Dec 2022	105K	-9.58M	-9131.43%

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA): Earnings per share (EPS)
2022-05-16	-0.68	-0.66
2022-08-15	-0.65	-0.54
2022-11-04	-0.49	-0.66

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA): Debt to assets
Mar 2022	30647000	5.82M	19.02%
Jun 2022	1270000	6.66M	524.49%
Sep 2022	14260000	6.10M	42.78%
Dec 2022	4581000	5.68M	123.99%

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA): Cash Flow
Mar 2022	-9.98M	0	44K
Jun 2022	-7.02M	0	44K
Sep 2022	-9.33M	0	468K
Dec 2022	-8.16M	-2K	-615K

Ayala Pharmaceuticals alternative data

Ayala Pharmaceuticals
Employees

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA): Employee count
Aug 2023	35
Sep 2023	35
Oct 2023	35
Nov 2023	35
Dec 2023	35
Jan 2024	35
Feb 2024	35
Mar 2024	35
Apr 2024	35
May 2024	35
Jun 2024	35
Jul 2024	35

Ayala Pharmaceuticals
Insider Trading

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA): Insider trades (number of shares)
Period	Buy	Sel
May 2020	1575225	0
Jul 2020	5	0
Aug 2020	5	0
Sep 2020	11	0
Dec 2020	4	0
Jan 2021	0	23872
Feb 2021	0	36126

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	24 Feb 2021	GORDON GARY B. officer: Chief Me..	Common Stock	3,000	$5.16	$15,480
Option	24 Feb 2021	GORDON GARY B. officer: Chief Me..	Stock Option	3,000	$5.16	$15,480
Sale	24 Feb 2021	GORDON GARY B. officer: Chief Me..	Common Stock	3,000	$5.16	$15,480
Sale	24 Feb 2021	MAMLUK RONI director, officer..	Common Stock	10,800	$17.4	$187,920
Sale	23 Feb 2021	MAMLUK RONI director, officer..	Common Stock	7,126	N/A	N/A
Sale	22 Feb 2021	MAMLUK RONI director, officer..	Common Stock	15,200	N/A	N/A
Sale	21 Jan 2021	MAMLUK RONI director, officer..	Common Stock	1,406	N/A	N/A
Option	20 Jan 2021	GORDON GARY B. officer: Chief Me..	Stock Option	3,000	N/A	N/A
Sale	20 Jan 2021	GORDON GARY B. officer: Chief Me..	Common Stock	3,000	N/A	N/A
Option	20 Jan 2021	GORDON GARY B. officer: Chief Me..	Common Stock	3,000	N/A	N/A

AYLA insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR TREATING NOTCH-ACTIVATED BREAST CANCER Filling date: 14 May 2020 Issue date: 4 Aug 2022	14 May 2020	4 Aug 2022
Application	Application COMPOSITIONS COMPRISING CD20 INHIBITORS AND BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THEREOF Filling date: 6 May 2019 Issue date: 9 Dec 2021	6 May 2019	9 Dec 2021
Application	Application COMBINATION COMPOSITIONS COMPRISING BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THEREOF Filling date: 5 May 2019 Issue date: 12 Aug 2021	5 May 2019	12 Aug 2021
Application	Application COMBINATION COMPOSITIONS COMPRISING BISFLUOROALKYL-1,4- BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THEREOF Filling date: 22 Oct 2020 Issue date: 11 Feb 2021	22 Oct 2020	11 Feb 2021
Application	Application COMBINATION OF IMMUNOTHERAPEUTICS AND BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR TREATING LYMPHOMAS Filling date: 24 Sep 2019 Issue date: 19 Mar 2020	24 Sep 2019	19 Mar 2020
Application	Application COMPOSITIONS COMPRISING BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR TREATING ADENOID CYSTIC CARCINOMA Filling date: 27 Sep 2019 Issue date: 23 Jan 2020	27 Sep 2019	23 Jan 2020

Ayala Pharmaceuticals
Executives

Insider	Age	Compensation
Mr. Yossi Maimon CPA, M.B.A., CPA, MBA (1971) Chief Financial Officer, Sec. & Treasurer	54	$692,180
Dr. Roni Mamluk Ph.D. (1967) Pres, Chief Executive Officer & Director	58	$635,600
Dr. Gary B. Gordon M.D., Ph.D. (1953) Chief Medical Officer	72	$550,310

Ayala Pharmaceuticals
Latest News

Wednesday, 19 October 2022
08:56	AYLA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Ayala Pharmaceuticals, Inc. Is Fair to Shareholders	businesswire.com
Tuesday, 13 September 2022
13:32	Ayala Pharmaceuticals, Inc. (AYLA) Upgraded to Buy: Here's Why	Zacks Investment Research
Wednesday, 24 August 2022
08:00	Ayala Pharmaceuticals Selected to Present Efficacy and Tolerability Data on AL102 in Desmoid Tumors at the European Society for Medical Oncology (ESMO) 2022 Congress	GlobeNewsWire
Tuesday, 16 August 2022
16:28	7 Short-Squeeze Stocks to Put on Your Must-Watch List	InvestorPlace
Monday, 15 August 2022
18:48	Ayala Pharmaceuticals, Inc. (AYLA) Reports Q2 Loss, Misses Revenue Estimates	Zacks Investment Research
Monday, 1 August 2022
13:27	Penny Stocks To Buy Now? 4 To Watch After LTRPB Stock Jumped Over 372%	PennyStocks
Thursday, 2 June 2022
08:00	Ayala Pharmaceuticals to Present at the 2022 Jefferies Global Healthcare Conference	GlobeNewsWire
Monday, 16 May 2022
18:48	Ayala Pharmaceuticals, Inc. (AYLA) Reports Q1 Loss, Misses Revenue Estimates	Zacks Investment Research
Monday, 28 March 2022
18:49	Ayala Pharmaceuticals, Inc. (AYLA) Reports Q4 Loss, Tops Revenue Estimates	Zacks Investment Research
Wednesday, 9 March 2022
08:00	Ayala Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference	GlobeNewsWire
Thursday, 6 January 2022
08:28	Ayala Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference	GlobeNewsWire
Thursday, 18 November 2021
11:28	How Much Upside is Left in Ayala Pharmaceuticals, Inc. (AYLA)? Wall Street Analysts Think 116%	Zacks Investment Research
Monday, 15 November 2021
13:55	Ayala Pharmaceuticals, Inc. (AYLA) Reports Q3 Loss, Misses Revenue Estimates	Zacks Investment Research
Wednesday, 10 November 2021
08:00	Ayala Pharmaceuticals to Present at Jefferies London Healthcare Conference	GlobeNewsWire
Tuesday, 9 November 2021
16:02	Earnings Preview: Ayala Pharmaceuticals, Inc. (AYLA) Q3 Earnings Expected to Decline	Zacks Investment Research
Thursday, 16 September 2021
15:44	Ayala Pharma Unveils New Interim Data From Rare Cancer Trial With AL101	Benzinga
Thursday, 2 September 2021
08:00	Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences	GlobeNewsWire
Friday, 13 August 2021
10:53	Ayala Pharmaceuticals, Inc. (AYLA) Reports Q2 Loss, Lags Revenue Estimates	Zacks Investment Research
08:49	Recap: Ayala Pharmaceuticals Q2 Earnings	Benzinga
08:00	Ayala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update	GlobeNewsWire

Frequently Asked Questions (FAQ)

When is Ayala Pharmaceuticals's next earnings date?

Unfortunately, Ayala Pharmaceuticals's (AYLA) next earnings date is currently unknown.
Does Ayala Pharmaceuticals pay dividends?

No, Ayala Pharmaceuticals does not pay dividends.
What is Ayala Pharmaceuticals's stock symbol?

Ayala Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "AYLA".
What is Ayala Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Ayala Pharmaceuticals?

Shares of Ayala Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Ayala Pharmaceuticals's key executives?
Ayala Pharmaceuticals's management team includes the following people:
- Mr. Yossi Maimon CPA, M.B.A., CPA, MBA Chief Financial Officer, Sec. & Treasurer(age: 54, pay: $692,180)
- Dr. Roni Mamluk Ph.D. Pres, Chief Executive Officer & Director(age: 58, pay: $635,600)
- Dr. Gary B. Gordon M.D., Ph.D. Chief Medical Officer(age: 72, pay: $550,310)
How many employees does Ayala Pharmaceuticals have?

As Jul 2024, Ayala Pharmaceuticals employs 35 workers.
When Ayala Pharmaceuticals went public?

Ayala Pharmaceuticals, Inc. is publicly traded company for more then 5 years since IPO on 8 May 2020.
What is Ayala Pharmaceuticals's official website?

The official website for Ayala Pharmaceuticals is ayalapharma.com.
How can i contact Ayala Pharmaceuticals?

Ayala Pharmaceuticals can be reached via phone at 857 444 0553.

Ayala Pharmaceuticals, Inc.

ayalapharma.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.

857 444 0553

4 Oppenheimer Street
Rehovot, 7670104

CIK: 0001797336
ISIN: US05465V1089
CUSIP: 05465V108